Published • loading... • Updated
PURE Bioscience Reports Fiscal 2026 Financial Results
Summary by HealthTech HotSpot
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
PURE Bioscience Reports Fiscal 2026 Financial Results
EL CAJON, Calif.--(BUSINESS WIRE)---- $PURE #Antimicrobial--PURE Bioscience, Inc. (OTCQB: PURE) (“PURE,” the “Company,” or “we”), creator of the patented non-toxic silver dihydrogen citrate (SDC) antimicrobial, today reported financial results for the fiscal year ended July 31, 2026. Summary of Results – Year-End Operations Net product sales were $2,315,000 and $2,198,000 for the fiscal years ended more...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
